AIM: The optimal antiproteinuric dose of aliskiren is unknown. This study compared the effect of placebo and increasing doses of aliskiren on urinary albumin excretion rate (UAER). METHODS: The trial was a double-blind crossover design. Twenty-six patients with type 2 diabetes mellitus, hypertension and albuminuria were randomised to 2-month treatments with placebo or aliskiren 150 mg, 300 mg or 600 mg once daily, in random order. Primary endpoint was change in UAER; secondary endpoints included changes in 24-h BP, GFR, biomarkers and components of the renin-angiotensin-aldosterone system. RESULTS:Placebo geometric mean UAER was 350 mg/day, mean 24-h BP was 137/81 (SD 12/9) mmHg, GFR was 85 (SD 26) ml min(-1) 1.73 m(-2). Aliskiren 150, 300 and 600 mg daily reduced UAER significantly by 36% (95% CI 17-51), 48% (33-60) and 52% (38-63) respectively (p < 0.001) compared with placebo. UAER reduction during the 600 mg dose was not significantly different from the 300 mg dose. Twenty-four-hour systolic BP was reduced by 4.5, 8.0 and 9.2 mmHg versus placebo, significant for 300 and 600 mg (p < or = 0.001). Twenty-four-hour diastolic BP was reduced by 3.0, 4.1 and 4.4 mmHg, significant versus placebo (p = 0.019, p = 0.001 and p < 0.001). GFR was reduced by 3.0, 5.1 and 6.5 ml min(-1) 1.73 m(-2). hsPRA was reduced by 63%, 70%, and 82% (p < 0.001 for all). Adverse events, most frequently dizziness and fatigue, occurred during all doses. CONCLUSIONS: In patients with type 2 diabetes mellitus, hypertension and albuminuria there is no improved antiproteinuric effect when using 600 mg aliskiren daily compared with the maximal recommended antihypertensive dose of 300 mg. TRIAL REGISTRATION: Clinicaltrials.gov NCT00464776 FUNDING: Novartis Pharma AG.
RCT Entities:
AIM: The optimal antiproteinuric dose of aliskiren is unknown. This study compared the effect of placebo and increasing doses of aliskiren on urinary albumin excretion rate (UAER). METHODS: The trial was a double-blind crossover design. Twenty-six patients with type 2 diabetes mellitus, hypertension and albuminuria were randomised to 2-month treatments with placebo or aliskiren 150 mg, 300 mg or 600 mg once daily, in random order. Primary endpoint was change in UAER; secondary endpoints included changes in 24-h BP, GFR, biomarkers and components of the renin-angiotensin-aldosterone system. RESULTS: Placebo geometric mean UAER was 350 mg/day, mean 24-h BP was 137/81 (SD 12/9) mmHg, GFR was 85 (SD 26) ml min(-1) 1.73 m(-2). Aliskiren 150, 300 and 600 mg daily reduced UAER significantly by 36% (95% CI 17-51), 48% (33-60) and 52% (38-63) respectively (p < 0.001) compared with placebo. UAER reduction during the 600 mg dose was not significantly different from the 300 mg dose. Twenty-four-hour systolic BP was reduced by 4.5, 8.0 and 9.2 mmHg versus placebo, significant for 300 and 600 mg (p < or = 0.001). Twenty-four-hour diastolic BP was reduced by 3.0, 4.1 and 4.4 mmHg, significant versus placebo (p = 0.019, p = 0.001 and p < 0.001). GFR was reduced by 3.0, 5.1 and 6.5 ml min(-1) 1.73 m(-2). hsPRA was reduced by 63%, 70%, and 82% (p < 0.001 for all). Adverse events, most frequently dizziness and fatigue, occurred during all doses. CONCLUSIONS: In patients with type 2 diabetes mellitus, hypertension and albuminuria there is no improved antiproteinuric effect when using 600 mg aliskiren daily compared with the maximal recommended antihypertensive dose of 300 mg. TRIAL REGISTRATION: Clinicaltrials.gov NCT00464776 FUNDING: Novartis Pharma AG.
Authors: B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245
Authors: F Persson; P Rossing; K J Schjoedt; T Juhl; L Tarnow; C D A Stehouwer; C Schalkwijk; F Boomsma; E Frandsen; H-H Parving Journal: Kidney Int Date: 2008-03-12 Impact factor: 10.612
Authors: Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg Journal: N Engl J Med Date: 2008-06-05 Impact factor: 91.245
Authors: K J Schjoedt; A S Astrup; F Persson; E Frandsen; F Boomsma; K Rossing; L Tarnow; P Rossing; H-H Parving Journal: Diabetologia Date: 2008-10-31 Impact factor: 10.122
Authors: Frederik Persson; Peter Rossing; Henrik Reinhard; Tina Juhl; Coen D A Stehouwer; Casper Schalkwijk; A H Jan Danser; Frans Boomsma; Erik Frandsen; Hans-Henrik Parving Journal: Diabetes Care Date: 2009-07-08 Impact factor: 19.112
Authors: Norman K Hollenberg; Naomi D L Fisher; Juerg Nussberger; George V Moukarbel; Ebrahim Barkoudah; A H Jan Danser Journal: J Hypertens Date: 2011-12 Impact factor: 4.844
Authors: Sergei I Petrykiv; Dick de Zeeuw; Frederik Persson; Peter Rossing; Ron T Gansevoort; Gozewijn D Laverman; Hiddo J L Heerspink Journal: Br J Clin Pharmacol Date: 2017-02-01 Impact factor: 4.335
Authors: Sergei I Petrykiv; Gozewijn Dirk Laverman; Frederik Persson; Liffert Vogt; Peter Rossing; Martin H de Borst; Ronald T Gansevoort; Dick de Zeeuw; Hiddo J L Heerspink Journal: Clin J Am Soc Nephrol Date: 2017-10-11 Impact factor: 8.237